Methylene Blue

SKU: orb1221954

Description

Methylene blue is a synthetic basic dye. Methylene blue stains to negatively charged cell components like nucleic acids; when administered in the lymphatic bed of a tumor during oncologic surgery, methylene blue may stain lymph nodes draining from the tumor, thereby aiding in the visual localization of tumor sentinel lymph nodes. When administered intravenously in low doses, this agent may convert methemoglobin to hemoglobin.(In Vitro):Methylene blue (Basic Blue 9) (4.5 μM; BV2 microglia) alters the immune profile of LPS-activated BV2 microglia and decreases the level of CD14, IL-1β, TNF-α, and CCL2 mRNA.(In Vivo):Methylene blue (Basic Blue 9) (50 and 100 mg/kg; i.p.; once, for 25 min; male NMRI mice) reduces absent prepulse inhibition. Methylene blue (Basic Blue 9) (20 and 40 mg/kg; p.o.; daily, for 6 months; CaMKIIα-tTA transactivator mice) preserves cognition in mice expressing full-length pro-aggregant human Tau.Methylene blue (Basic Blue 9) (2 mg/kg; i.v.; once, for 1 d; TBI-treated male BALB/c mice) reduces TBI-induced edema and neuroinflammation and reduces acute depression-like behavior. Methylene blue (Basic Blue 9) (2 mg/kg; i.v.; once, for 1 d; TBI-treated male BALB/c mice) reduces the percentage of inflammatory factor.

Key Properties

• CAS Number: 61-73-4
• MW: 319.85
• Purity: >98% (HPLC)
• Formula: C₁₆H₁₈ClN₃S
• SMILES: [Cl-].CN(C)c1ccc2nc3ccc(cc3sc2c1)=[N+](C)C
• Target: NF-κB
• Solubility: H2O : ≥ 50 mg/mL; 156.32 mM

Bioactivity

• In Vivo:
  Methylene blue (Basic Blue 9) (50 and 100 mg/kg; i.p.; once, for 25 min; male NMRI mice) reduces absent prepulse inhibition. Methylene blue (Basic Blue 9) (20 and 40 mg/kg; p.o. ; daily, for 6 months; CaMKIIα-tTA transactivator mice) preserves cognition in mice expressing full-length pro-aggregant human Tau. Methylene blue (Basic Blue 9) (2 mg/kg; i. v. ; once, for 1 d; TBI-treated male BALB/c mice) reduces TBI-induced edema and neuroinflammation and reduces acute depression-like behavior. Methylene blue (Basic Blue 9) (2 mg/kg; i. v. ; once, for 1 d; TBI-treated male BALB/c mice) reduces the percentage of inflammatory factor. Animal model: Male NMRI mice. Dosage: 50 and 100 mg/kg. Administration: Intraperitoneal injection; once, for 25 minutes. Result: Reduced the prepulse inhibition and reduced the increase in locomotor activity caused by phencyclidine (PCP). Animal model: CaMKIIα-tTA transactivator mice. Dosage: 20 and 40 mg/kg. Administration: Oral administration; daily, for 6 months. Result: Inhibited Tau aggregation in CaMKIIα-tTA transactivator mice. Animal model: TBI-treated male BALB/c mice. Dosage: 2 mg/kg. Administration: Intravenous injection; once, for 1 day. Result: Decreased the level of CD14, IL-1β, TNF-α, and CCL2 mRNA. Animal model: TBI-treated male BALB/c mice. Dosage: 2 mg/kg. Administration: Intravenous injection; once, for 1 day. Result: Reduced the percentage of myeloid (CD11b+/GR1+) cells, reduced IL-1β and enhanced IL-10 expression in microglia.
  Read more...
• In Vitro:
  Methylene blue (Basic Blue 9) (4.5 μM; BV2 microglia) alters the immune profile of LPS-activated BV2 microglia and decreases the level of CD14, IL-1β, TNF-α, and CCL2 mRNA.
  Read more...

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Methylene blue | CI52015

Quick Database Links

Gene Symbol

NF-κB